PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
SLNO vs. ALAR
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SLNO and ALAR is 0.13, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

SLNO vs. ALAR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Soleno Therapeutics, Inc. (SLNO) and Alarum Technologies Ltd. (ALAR). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%40.00%SeptemberOctoberNovemberDecember2025February
-4.59%
-46.14%
SLNO
ALAR

Key characteristics

Sharpe Ratio

SLNO:

-0.14

ALAR:

-0.40

Sortino Ratio

SLNO:

0.20

ALAR:

0.05

Omega Ratio

SLNO:

1.02

ALAR:

1.01

Calmar Ratio

SLNO:

-0.08

ALAR:

-0.47

Martin Ratio

SLNO:

-0.49

ALAR:

-0.85

Ulcer Index

SLNO:

15.65%

ALAR:

55.42%

Daily Std Dev

SLNO:

56.18%

ALAR:

117.21%

Max Drawdown

SLNO:

-99.86%

ALAR:

-99.94%

Current Drawdown

SLNO:

-93.16%

ALAR:

-99.73%

Fundamentals

Market Cap

SLNO:

$1.93B

ALAR:

$49.33M

EPS

SLNO:

-$2.79

ALAR:

$1.30

Total Revenue (TTM)

SLNO:

$0.00

ALAR:

$24.45M

Gross Profit (TTM)

SLNO:

-$984.00K

ALAR:

$18.57M

EBITDA (TTM)

SLNO:

-$124.16M

ALAR:

$6.50M

Returns By Period

In the year-to-date period, SLNO achieves a -0.20% return, which is significantly higher than ALAR's -34.87% return.


SLNO

YTD

-0.20%

1M

-6.66%

6M

-8.52%

1Y

-12.89%

5Y*

2.38%

10Y*

-21.03%

ALAR

YTD

-34.87%

1M

-29.49%

6M

-49.04%

1Y

-55.71%

5Y*

-17.58%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

SLNO vs. ALAR — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SLNO
The Risk-Adjusted Performance Rank of SLNO is 3939
Overall Rank
The Sharpe Ratio Rank of SLNO is 3939
Sharpe Ratio Rank
The Sortino Ratio Rank of SLNO is 3838
Sortino Ratio Rank
The Omega Ratio Rank of SLNO is 3737
Omega Ratio Rank
The Calmar Ratio Rank of SLNO is 4242
Calmar Ratio Rank
The Martin Ratio Rank of SLNO is 3737
Martin Ratio Rank

ALAR
The Risk-Adjusted Performance Rank of ALAR is 2828
Overall Rank
The Sharpe Ratio Rank of ALAR is 2626
Sharpe Ratio Rank
The Sortino Ratio Rank of ALAR is 3434
Sortino Ratio Rank
The Omega Ratio Rank of ALAR is 3434
Omega Ratio Rank
The Calmar Ratio Rank of ALAR is 1919
Calmar Ratio Rank
The Martin Ratio Rank of ALAR is 2828
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SLNO vs. ALAR - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Soleno Therapeutics, Inc. (SLNO) and Alarum Technologies Ltd. (ALAR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for SLNO, currently valued at -0.14, compared to the broader market-3.00-2.00-1.000.001.002.003.00-0.14-0.40
The chart of Sortino ratio for SLNO, currently valued at 0.20, compared to the broader market-4.00-2.000.002.004.000.200.05
The chart of Omega ratio for SLNO, currently valued at 1.02, compared to the broader market0.501.001.502.001.021.01
The chart of Calmar ratio for SLNO, currently valued at -0.19, compared to the broader market0.002.004.006.00-0.19-0.47
The chart of Martin ratio for SLNO, currently valued at -0.49, compared to the broader market-10.000.0010.0020.00-0.49-0.85
SLNO
ALAR

The current SLNO Sharpe Ratio is -0.14, which is higher than the ALAR Sharpe Ratio of -0.40. The chart below compares the historical Sharpe Ratios of SLNO and ALAR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.00SeptemberOctoberNovemberDecember2025February
-0.14
-0.40
SLNO
ALAR

Dividends

SLNO vs. ALAR - Dividend Comparison

Neither SLNO nor ALAR has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SLNO vs. ALAR - Drawdown Comparison

The maximum SLNO drawdown since its inception was -99.86%, roughly equal to the maximum ALAR drawdown of -99.94%. Use the drawdown chart below to compare losses from any high point for SLNO and ALAR. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-29.30%
-99.73%
SLNO
ALAR

Volatility

SLNO vs. ALAR - Volatility Comparison

The current volatility for Soleno Therapeutics, Inc. (SLNO) is 10.38%, while Alarum Technologies Ltd. (ALAR) has a volatility of 14.67%. This indicates that SLNO experiences smaller price fluctuations and is considered to be less risky than ALAR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%SeptemberOctoberNovemberDecember2025February
10.38%
14.67%
SLNO
ALAR

Financials

SLNO vs. ALAR - Financials Comparison

This section allows you to compare key financial metrics between Soleno Therapeutics, Inc. and Alarum Technologies Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab